{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:20:25Z","timestamp":1783639225964,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.clineuro.2010.06.018","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T08:37:51Z","timestamp":1279787871000},"page":"781-784","source":"Crossref","is-referenced-by-count":16,"title":["Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial"],"prefix":"10.1016","volume":"112","author":[{"given":"J\u00f6rn Peter","family":"Sieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2010.06.018_bib1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2010.06.018_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/clpt.1985.78","article-title":"Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis","volume":"37","author":"Breyer-Pfaff","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clineuro.2010.06.018_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/WNL.26.6.536","article-title":"The pharmacokinetics of pyridostigmine","volume":"26","author":"Cohan","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2010.06.018_bib4","first-page":"253","article-title":"Therapy of myasthenia gravis","volume":"vol. 91","author":"Drachman","year":"2008"},{"key":"10.1016\/j.clineuro.2010.06.018_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2010.06.018_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.37.5.800","article-title":"Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis","volume":"37","author":"Milner-Brown","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2010.06.018_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2007-1001967","article-title":"Serumspiegel von Pyridostigmin bei Myasthenia gravis: Methoden und klinische Bedeutung","volume":"53","author":"Schumm","year":"1985","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.1016\/j.clineuro.2010.06.018_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0028-1090147","article-title":"Retardiertes Pyridostigmin in der Myasthenie-Behandlung - Ergebnisse einer nicht-interventionellen Beobachtungsstudie","volume":"36","author":"Sieb","year":"2009","journal-title":"Aktuel Neurol"},{"key":"10.1016\/j.clineuro.2010.06.018_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life. The EuroQol Group","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.clineuro.2010.06.018_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.31.2.145","article-title":"Plasma pyridostigmine levels in myasthenia gravis","volume":"31","author":"White","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2010.06.018_bib11","series-title":"Der Cholinesterasehemmer MESTINON\u00ae. Kurz\u00fcbersicht zu Eigenschaften und Wirkungen","year":"2000"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846710001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846710001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T11:55:31Z","timestamp":1544356531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846710001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0303846710001952"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2010.06.018","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}